Carcinogenesis, Vol. 24, No. 3, 443-451,
March 2003
© 2003 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells
1 Department of Medicine, Ruhr-University Bochum, Knappschaftskrankenhaus,
2 Department of Gastroenterology and Hepatology, Bergmannsheil, Germany
Non-steroidal anti-inflammatory drugs (NSAID) may inhibit colon cancer development through affecting proliferation and apoptosis. However, their use in cancer chemoprevention is still limited due to toxicities. There is longstanding clinical experience with the aminosalicylate mesalazine in the treatment of patients with inflammatory bowel disease with very few side effects. So far, most studies on the cellular effects of mesalazine were focused on its anti-inflammatory properties. Recent data, however, indicate that mesalazine may also reduce cell growth in vivo. We therefore investigated the growth inhibitory effect of mesalazine on human colon cancer cells in vitro compared with established chemopreventive agents. We also wished to determine the underlying cellular mechanisms of the effect. Here we show that mesalazine dose- and time-dependently inhibited the proliferation of colon cancer cells. Mesalazine was less potent in reducing cell growth than sulindac sulfide or indomethacin but growth effective mesalazine concentrations were comparable with concentrations achievable in vivo under standard mesalazine treatment. While other NSAID induced a robust G1 arrest, mesalazine specifically blocked cells in mitosis although microtubule polymerization or spindle orientation was not affected. In addition, mesalazine induced apoptosis in colon cancer cells possibly through activation of caspase-3 whereas the levels of bcl-2 family proteins were not altered. We conclude that mesalazine inhibits growth of colon cancer cells largely through a mitotic arrest, which has not been reported for NSAID so far. Mesalazine also induces apoptosis through partial activation of caspases similar to, although weaker than, established chemopreventive agents. These findings may suggest a potential of mesalazine as a chemopreventive agent for colorectal cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. J. Koelink, E. C. Robanus-Maandag, P. Devilee, D. W. Hommes, C. B.H.W. Lamers, and H. W. Verspaget 5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model Carcinogenesis, July 1, 2009; 30(7): 1217 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Das, M. Bajpai, Y. Kong, J. Liu, X. Geng, and K. M. Das Mesalamine Suppresses the Expression of TC22, a Novel Tropomyosin Isoform Associated with Colonic Neoplasia Mol. Pharmacol., July 1, 2009; 76(1): 183 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schwab, V. Reynders, S. Loitsch, Y. M. Shastri, D. Steinhilber, O. Schroder, and J. Stein PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells Carcinogenesis, July 1, 2008; 29(7): 1407 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stolfi, D. Fina, R. Caruso, F. Caprioli, M. C. Fantini, A. Rizzo, M. Sarra, F. Pallone, and G. Monteleone Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase Carcinogenesis, June 1, 2008; 29(6): 1258 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M.Y. Tin, C.-H. Cho, K. Chan, A. E. James, and J. K.S. Ko Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft Carcinogenesis, June 1, 2007; 28(6): 1347 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bos, S. H. Diks, J. C.H. Hardwick, K. V. Walburg, M. P. Peppelenbosch, and D. J. Richel Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/{beta}-catenin pathway activity Carcinogenesis, December 1, 2006; 27(12): 2371 - 2382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C R Boland, M G Luciani, C Gasche, and A Goel INFECTION, INFLAMMATION, AND GASTROINTESTINAL CANCER Gut, September 1, 2005; 54(9): 1321 - 1331. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gasche, A. Goel, L. Natarajan, and C. R. Boland Mesalazine Improves Replication Fidelity in Cultured Colorectal Cells Cancer Res., May 15, 2005; 65(10): 3993 - 3997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rousseaux, B. Lefebvre, L. Dubuquoy, P. Lefebvre, O. Romano, J. Auwerx, D. Metzger, W. Wahli, B. Desvergne, G. C. Naccari, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-{gamma} J. Exp. Med., April 18, 2005; 201(8): 1205 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Masala, S Bagnoli, M Ceroti, C Saieva, G Trallori, I Zanna, G d'Albasio, and D Palli Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001 Gut, September 1, 2004; 53(9): 1309 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Selvakumar, A. Lakshmikuttyamma, R. Kanthan, S. C. Kanthan, J. R. Dimmock, and R. K. Sharma High Expression of Methionine Aminopeptidase 2 in Human Colorectal Adenocarcinomas Clin. Cancer Res., April 15, 2004; 10(8): 2771 - 2775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Huguenin, F. Vacherot, L. Kheuang, J. Fleury-Feith, M.-C. Jaurand, M. Bolla, J.-P. Riffaud, and D. K. Chopin Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines Mol. Cancer Ther., March 1, 2004; 3(3): 291 - 298. [Abstract] [Full Text]
|
|